Japan will receive 150 million doses of U.S. pharmaceutical giant Novavax Inc.’s COVID-19 vaccine from as early as the beginning of 2022, the health ministry said Tuesday.
The ministry said it has signed a deal with Japan’s Takeda Pharmaceutical Co., which will handle manufacturing and distribution of the Novavax vaccine in Japan. Takeda and Novavax are currently developing the vaccine, aiming to use it as a booster and also to make it effective against coronavirus variants.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.